This clinical trial is a study to evaluate the pharmacokinetics of the tablet formulation Pociredir in fasted and fed state participants with Sickle Cell Disease (SCD).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Plasma concentration of pociredir under fasted and fed conditions
Timeframe: Day 1 through Day 4
Maximum plasma concentration (Cmax) of pociredir under fasted and fed conditions
Timeframe: Day 1 through Day 4
Area under the plasma concentration-time curve from time 0 to 24 hours (AUC(0-24)) of pociredir under fasted and fed conditions
Timeframe: Day 1 through Day 4
Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC(0-tlast)) of pociredir under fasted and fed conditions
Timeframe: Day 1 through Day 4
Area under the plasma concentration-time curve from time 0, extrapolated to infinity (AUC(0-inf)), of pociredir under fasted and fed conditions
Timeframe: Day 1 through Day 4
Time to maximum plasma concentration (Tmax) of pociredir under fasted and fed conditions
Timeframe: Day 1 through Day 4
Terminal disposition rate constant (λz) of pociredir under fasted and fed conditions
Timeframe: Day 1 through Day 4
Terminal half-life (t1/2) of pociredir under fasted and fed conditions
Timeframe: Day 1 through Day 4
Apparent volume of distribution during the terminal phase (Vz/F) of pociredir under fasted and fed conditions
Timeframe: Day 1 through Day 4
Apparent clearance (CL/F) of pociredir under fasted and fed conditions
Timeframe: Day 1 through Day 4